Second primary lung cancer

Antakli, Tamim; Schaefer, Robert F.; Rutherford, Jerry E.; Read, Raymond C.

doi:10.1016/0003-4975(95)00067-u

Cited by 174 publications

(124 citation statements)

References 23 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…The criteria defined by Martini and Antakli are used to divide the tumors as synchronous and metachronous (1)(2)(3)(4). If tumors are present at the same time, they must be separated and the histology must be different.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A rare synchronous tumor: primary squamous cell lung cancer and adenoid cystic carcinoma of the tongue

Karadeniz¹,

Yaşar²,

Üçsular³

et al. 2017

Tuberk Toraks

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Surgery is the standard option when feasible in multiple primary cancers (1)(2)(3)(4)(5)(6)(7)(8). In our case endobronchial therapy for airway obstruction and palliative radiotherapy for tongue performed because of poor performance and advanced stage of cancers.…”

Section: Discussionmentioning

confidence: 99%

A rare synchronous tumor: primary squamous cell lung cancer and adenoid cystic carcinoma of the tongue

Karadeniz¹,

Yaşar²,

Üçsular³

et al. 2017

Tuberk Toraks

View full text Add to dashboard Cite

“…On the other hand, the benefits of earlier intervention may represent a subset with differences in the biology of disease or other unknown factors (Thomas and Rubinstein, 1990;Faber, 1993;Antakli et al, 1995;Martini et al, 1999;Downey, 1999). Moreover, in the setting of prevention, other issues have to be considered, such as smoking cessation, carcinogenesis/chemoprevention studies and the use of new genetic tools able to characterise molecular markers of risk and drug activity.…”

Section: Discussionmentioning

confidence: 99%

Persistent excess mortality from lung cancer in patients with stage I non-small-cell lung cancer, disease-free after 5 years

et al. 2003

View full text Add to dashboard Cite

Among patients with non-small-cell lung cancer (NSCLC), those with pathological stage I have the best expectation of survival; however, survival is reduced to less than 50% in the long term. At present, it is unclear when patients can be reasonably defined as cured, and if they experience a higher incidence of malignant/nonmalignant diseases and a lower expectation of survival than the general population. A total of 134 stage I NSCLC patients, who had undergone resection at the Thoracic Surgery Unit of the General Hospital of Verona (north-eastern Italy) from October 1987 to December 1993, were still disease-free at 5 years. These subjects were further followed up, and morbidity and mortality rates were compared with those recorded in the general population of the same geographical area. The standardised incidence ratios (SIRs) for all malignancies and for lung cancer were higher than expected (2.39, 95% CI ¼ 1.6 -3.5, Po0.001; 10.1, 95% CI ¼ 6.2 -15.6, Po0.0001, respectively). The standardised mortality ratio (SMR) was also significantly increased (1.73, 95% CI ¼ 1.1 -2.6, P ¼ 0.013). The excess mortality could be entirely explained by an increase in mortality from lung cancer (5.7, 95% CI ¼ 2.8 -10.1, Po0.0001). This study shows that patients, resected for pathological stage I NSCLC and tumour-free after 5 years, have a higher incidence of new lung cancer compared with the general population, which in turn determines an excess in all-cause mortality in the following years.

show abstract

“…Many surgeons use the Martini and Melamed (10) and Antaklı et al (11) criteria for diagnosis. However, these criteria exhibit uncertainties regarding satellite tumors.…”

Section: Satellite Tumorsmentioning

confidence: 99%

“…There are significantly different results regarding survival in synchronous tumors [11,15]. The possible cause of this variability is the heterogenicity of patient populations and treatment methods.…”

Section: Synchronous Lung Cancermentioning

confidence: 99%

Synchronous, Metachronous or Metastases?

Kocatürk¹

2018

Eur J Ther

View full text Add to dashboard Cite

Multiple primer lung cancer (MPAK) satellite tumors (accessory tumor of the same type with the same tumor in the same lobe) synchronous tumors (at the time of diagnosis, or at the same site within 3 months or with other tumors in the opposite lung) and metachronous tumors (a newly developed tumor in a patient with a definitively treated tumor). Satellite tumors are synchronous tumors also. It may be difficult to understand whether MPAC is primer tumors originating from different areas of the lung, or whether they are metastases from each other. If the histopathological types of the tumors are different from each other, it can be said that they are generally MPAK. However, if histopathological types are the same, histopathological, molecular, genetic and clinical data are needed. It is useful to demonstrate histopathologically that the detailed analysis of tumors (subtype, dominant type, especially in adenocarcinomas) and carcioma insitu background. Genetic and molecular tests are still a matter of debate. It is both very expensive and can be performed in a small number of centers, and not at the expected activity. Because the cancer cells are very complex and constantly undergoing mutation and change. The clinical criteria, especially the Martini-Melamed criteria have been used for a long time. It is still valid. If the histopathological types are different for metachronous tumors, there is no problem, but if they are the same, the second tumor is defined according to the development time. However, it may be more accurate to evaluate these patients independently from time to time. The best survival data is obtained with surgery even if it is second cancer or local recurrence or metachronous cancer Therefore, if patients with synchronous or metachronous cancer are considered to have no distant metastasis or mediastinal involvement, surgical treatment should be the priority.

show abstract

Second primary lung cancer

Cited by 174 publications

References 23 publications

A rare synchronous tumor: primary squamous cell lung cancer and adenoid cystic carcinoma of the tongue

A rare synchronous tumor: primary squamous cell lung cancer and adenoid cystic carcinoma of the tongue

Persistent excess mortality from lung cancer in patients with stage I non-small-cell lung cancer, disease-free after 5 years

Synchronous, Metachronous or Metastases?

Contact Info

Product

Resources

About